Dianthus Therapeutics stock shot higher Monday after the company said it would advance its experimental CIDP treatment.

Lead antibody MB0109 targets C1q and uniquely inhibits both classical complement cascade and C1q-mediated macrophage/microglial activation — two key drivers of neuroinflammationMB0109 demonstrated ...

Growing tomatoes successfully hinges on one of a few critical factors: one of them being location. Where you plant your ...

Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $30.91, along ...

We may be entering a period defined by fiscal strain, geopolitical fragmentation, energy expansion and policy volatility.

Apellis Pharmaceuticals (NASDAQ:APLS) executives outlined a three-part strategy for the company at TD Cowen’s 46th Annual ...

Nothing feels more rejuvenating after a strenuous hike than a long soak in a natural hot spring. Luckily, there are places in ...

While the strategies didn’t lower NT-proBNP after PCI in acute MI patients, they may suggest a way forward for intervening early.

Spinal cord injury often triggers a cascade of secondary damage that severely limits functional recovery, largely driven by ...

India has always known, at its civilisational depth, that the feminine is not peripheral. It is foundational. From the ...

Positive results from Phase 3 ADAPT OCULUS study show VYVGART’s potential as the first targeted treatment for patients ...